Clear Street Reiterates Buy Rating on Palvella Therapeutics (PVLA) following BEYOND mLM disease-awareness campaign launch
Tweet Send to a Friend
Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $220.00 price target on Palvella Therapeutics (NASDAQ: PVLA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
